IFAP Syndrome 1 (MONDO:0100213): Comprehensive Disease Characteristics Report

Summary

IFAP Syndrome 1 (Ichthyosis Follicularis, Atrichia, and Photophobia syndrome; OMIM #308205; MONDO:0100213; Orphanet ORPHA:2273) is an ultra-rare X-linked recessive genodermatosis defined by a congenital clinical triad of ichthyosis follicularis (generalized spiny, keratotic follicular papules), atrichia/alopecia (near-total loss of scalp hair, eyebrows, and eyelashes), and photophobia arising from a progressive, vascularizing keratopathy. The disorder is caused by hypomorphic (partial loss-of-function) missense and splice-site variants in MBTPS2 (membrane-bound transcription factor peptidase, site 2; Xp22.12), which encodes an intramembrane zinc metalloprotease known as site-2 protease (S2P). Because MBTPS2 is on the X chromosome, affected individuals are predominantly male; female carriers may show mosaic, Blaschko-linear cutaneous lesions due to lyonization.

Mechanistically, S2P performs regulated intramembrane proteolysis (RIP) — it makes the second, membrane-embedded cleavage that liberates the active transcription-factor domains of SREBP (sterol regulatory element-binding protein, master regulator of cholesterol and fatty-acid synthesis) and ATF6 (the ER-stress/unfolded-protein-response arm). Partial loss of S2P activity therefore simultaneously impairs epidermal barrier lipid synthesis and cripples the ER-stress response, disrupting terminal differentiation of epidermis, hair follicles, and the corneal/limbal epithelium. A key genotype–phenotype principle emerges: the amount of residual protease activity correlates inversely with clinical severity, generating a continuum that extends from isolated IFAP to the lethal multisystem BRESHECK syndrome. MBTPS2 is allelic with several other Mendelian disorders (KFSD, X-linked Olmsted syndrome, and X-linked osteogenesis imperfecta type XIX), and phenocopies of the ichthyosis-follicularis phenotype are produced by variants in SREBF1 (autosomal-dominant IFAP/hereditary mucoepithelial dysplasia) and GJB2.

There is no curative therapy. Management is symptomatic and multidisciplinary: emollients/keratolytics (urea) for skin, aggressive ocular-surface protection (lubrication, prophylactic antibiotics, punctal occlusion, tarsorrhaphy, amniotic membrane transplantation), and, in several reports, systemic acitretin (~1 mg/kg), which yields partial improvement of cutaneous and corneal features but does not reverse alopecia or photophobia. Genetic counseling is essential given X-linked inheritance. This report compiles nine confirmed findings across 28 reviewed papers into a structured knowledge-base entry.

Key Findings

Finding 1 — MBTPS2 hypomorphic variants cause IFAP Syndrome 1

IFAP Syndrome 1 is caused by hypomorphic missense variants in MBTPS2, an X-linked gene encoding site-2 protease. The seminal mapping and gene-identification study by Oeffner et al. (2009) localized the IFAP locus to Xp22.11–p22.13 (a 5.4-Mb interval between markers DXS989 and DXS8019) and identified missense mutations that exchange highly conserved amino-acid residues. Critically, the authors demonstrated a quantitative genotype–phenotype relationship: using functional complementation in Chinese hamster M19 cells (which lack endogenous S2P), they showed that five patient mutations impaired SRE-regulated reporter induction and growth in cholesterol/lipid-free medium, and that the degree of diminished protease activity correlated with clinical severity in male patients.

"missense mutations exchanging highly conserved amino acids of membrane-bound transcription factor protease, site 2 (MBTPS2) are associated with this phenotype" — PMID: 19361614

"The degree of diminished activity correlated with clinical severity as noted in male patients" — PMID: 19361614

Key identifiers: MONDO:0100213 · OMIM #308205 (disease) · MBTPS2 OMIM 300294 · HGNC:7375 · cytogenetic locus Xp22.12*.

Finding 2 — Dual mechanism: RIP of SREBP (cholesterol homeostasis) and ATF6 (ER stress)

MBTPS2/S2P is a membrane-embedded zinc metalloprotease that activates signaling substrates by cleaving them within the lipid bilayer (regulated intramembrane proteolysis). Its two best-characterized substrates are SREBP (SREBF; controls lipid biosynthesis) and ATF6 (the ER-stress/UPR transcription factor). The pathogenicity of MBTPS2 variants was directly demonstrated by Strong et al. (2022), who studied a BRESHECK-associated variant, c.766G>A (p.Val256Leu), and found it impaired growth in cholesterol-depleted medium, attenuated SREBP-pathway activation, and abolished the ER-stress (UPR) response in vitro — establishing that both arms of S2P signaling are compromised.

"impaired cell growth in cholesterol-depleted media, attenuated activation of the sterol regulatory element-binding protein pathway, and failure to activate the endoplasmic reticulum stress response pathway" — PMID: 34655156

"cleaves and activates several signaling and regulatory proteins from the membrane" — PMID: 33743732

Finding 3 — Clinical triad, X-linked inheritance, and the allelic disorder spectrum

IFAP is defined by the triad of ichthyosis follicularis (follicular keratotic/spiny papules), atrichia/alopecia (scalp, eyebrows, eyelashes), and photophobia. Additional recurrent features include palmoplantar keratoderma, nail dystrophy, recurrent infections, xerosis, and angular cheilitis. Inheritance is X-linked recessive, so affected individuals are predominantly male; female carriers display mosaic, Blaschko-linear lesions attributable to X-chromosome inactivation (lyonization). At the severe end of the spectrum lies BRESHECK syndrome (the IFAP triad plus intellectual disability and multiple congenital anomalies). MBTPS2 is allelic to Keratosis Follicularis Spinulosa Decalvans (KFSD), Olmsted syndrome (X-linked form), and Osteogenesis Imperfecta type XIX.

"IFAP) syndrome is a rare autosomal recessive, X-linked, genetic disorder that involves a triad of follicular ichthyosis, atrichia of the scalp, and photophobia" — PMID: 38089015

"BRESHECK syndrome, characterized by the IFAP triad plus intellectual disability and multiple congenital anomalies" — PMID: 34655156

"Ichthyosis Follicularis, Atrichia and Photophobia syndrome (IFAP) with or without BRESHECK syndrome, Keratosis Follicularis Spinulosa Decalvans (KFSD), Olmsted syndrome, and Osteogenesis Imperfecta type XIX" — PMID: 33743732

X-linked skin-disease mosaicism in female carriers is documented in PMID: 16720460.

Finding 4 — Ophthalmic disease is a progressive keratopathy driven by limbal stem-cell dysfunction

The photophobia of IFAP reflects a serious, progressive corneal disease. In males, ocular features include severe photophobia, corneal erosions/epithelial defects, superficial and deep corneal (neo)vascularization, corneal scarring, and progressive vision loss (down to counting-fingers acuity) (Traboulsi 2004). Basilious et al. (2020) used anterior-segment OCT to document bilateral limbal thickening, peripheral corneal pannus, conjunctivalization, and abnormal hyperreflective epithelium — a constellation "highly suggestive of limbal stem cell dysfunction." Carrier mothers can show retinal vascular tortuosity as an ocular sign of carrier status.

"The progressive conjunctivalization, spontaneous epithelial defects, and anterior segment optical coherence tomography features are highly suggestive of limbal stem cell dysfunction in IFAP syndrome" — PMID: 32482964

"Males with IFAP have an inexorable progression of corneal vascularization and loss of vision. Retinal vascular tortuosity may be another clinical sign of carrier status in females" — PMID: 15370546

Finding 5 — Management is symptomatic; systemic acitretin gives partial benefit

No curative therapy exists; care is symptomatic and multidisciplinary. The systemic retinoid acitretin (~1 mg/kg) produced moderate improvement in cutaneous features and corneal erosions but no change in alopecia or photophobia over 6 months (Khandpur 2005). A separate case reported significant improvement of photophobia, corneal erosions, and neuropsychomotor development with acitretin plus amniotic membrane transplantation (Höpker 2011). Ocular-surface optimization employs aggressive lubrication, prophylactic antibiotics, punctal occlusion, tarsorrhaphy, and amniotic membrane transplantation; skin care relies on emollients and urea-based keratolytics (Bin Rubaian 2023). Orthopedic surgery (soft-tissue release, tendon lengthening) may be required for contractures (Ghaznavi 2025).

"A moderate response to acitretin therapy (1 mg/kg) administered for 6 months was observed, with improvement in cutaneous features and corneal erosions and no change in alopecia or photophobia" — PMID: 16268889

"After three months using systemic retinoid (Acitretina) and posterior amniotic membrane transplantation in the left eye, there was a significant improvement of photophobia, corneal erosions and neuropsychomotor development" — PMID: 21670910

Finding 6 — Epidemiology, diagnosis, and variable expressivity of identical variants

IFAP is very rare (Orphanet ORPHA:2273); approximately 40 male cases had been reported by 2018, and no precise prevalence/incidence figures exist. Diagnosis rests on recognition of the clinical triad plus MBTPS2 sequencing (single-gene testing or whole-exome sequencing). Both missense and splice-site variants are pathogenic. A striking example of variable expressivity is the recurrent intronic variant c.671-9T>G, which caused typical IFAP with Olmsted-like keratoderma in one patient but IFAP without keratoderma in two others (Wang 2014); the intronic variant c.970+5G>A causes exon-7 skipping (Chen 2023). The BRESHECK acronym expands to Brain anomalies, Retardation of mentality/growth, Ectodermal dysplasia, Skeletal malformations, Hirschsprung disease, Ear deformity/deafness, Eye hypoplasia, Cleft palate, Cryptorchidism, and Kidney dysplasia/hypoplasia.

"this mutation was previously reported in two cases of IFAP without keratoderma, which suggests clinical heterogeneicity of the same mutation in MBTPS2" — PMID: 24313295

"BRESHECK (brain anomalies, retardation of mentality and growth, ectodermal dysplasia, skeletal malformations, Hirschsprung disease, ear deformity and deafness, eye hypoplasia, cleft palate, cryptorchidism, and kidney dysplasia/hypoplasia) syndrome" — PMID: 24313295

"A total of 40 cases has been reported" — PMID: 28654459

Finding 7 — Molecular pathway placement: S2P is the second protease in sequential SCAP–SREBP and ATF6 cleavage, linking lipogenesis to immunity

The SREBP pathway operates as a two-cut cascade: SCAP escorts SREBP from the ER to the Golgi, where site-1 protease (S1P/MBTPS1) makes the first cut, then site-2 protease (S2P/MBTPS2) makes the intramembrane cut that releases the active transcription-factor domain, upregulating lipid-biosynthesis genes (Ozdemir & Rawson 2011). The identical S1P/S2P machinery cleaves ATF6 during ER stress. Importantly, the Scap–SREBP1–S1P/S2P cascade also spatiotemporally controls NF-κB: upon LPS stimulation, SREBP1 cleavage at the Golgi liberates IκBα for IKK phosphorylation and NF-κB activation, and inhibiting S2P diminishes LPS-induced NF-κB and inflammatory responses (Fei et al. 2023). This connects S2P loss to the recurrent infections seen in IFAP.

"when demand for lipid rises, SREBP travels from the endoplasmic reticulum to the Golgi apparatus where it is cleaved by two distinct proteases" — PMID: 20935466

"Loss of Scap or inhibition of S1P or S2P diminishes, while SREBP1 deficiency augments, LPS-induced NF-κB activation and subsequent inflammatory responses" — PMID: 37267109

Finding 8 — Model organisms and deep evolutionary conservation of S2P

Site-2 protease is evolutionarily ancient and conserved. In Drosophila melanogaster, dS2P null mutants (and dSREBP/dScap mutants) have been isolated and display lipid-auxotrophy phenotypes rescuable by dietary lipids (Ozdemir & Rawson 2011). Mammalian S2P function was originally defined using Chinese hamster ovary M19 cells, which lack S2P and therefore require exogenous cholesterol/lipids; wild-type human MBTPS2 complements this defect, whereas IFAP patient variants fail to fully complement (Oeffner 2009). No dedicated Mbtps2 mouse or zebrafish IFAP disease model was retrieved in this investigation; the CHO-M19 complementation assay remains the principal functional model used to classify MBTPS2 variant pathogenicity.

"we isolated Drosophila mutants null for dsrebp and others lacking site-2 protease (ds2p), the second of two Golgi-resident proteases that cleave dSREBP" — PMID: 20935466

"Wild-type MBTPS2 was able to complement the protease deficiency in Chinese hamster M19 cells" — PMID: 19361614

Finding 9 — Ichthyosis follicularis is genetically heterogeneous; S2P-mutant fibroblast omics reveal a lipid/collagen signature

The ichthyosis-follicularis phenotype is not specific to MBTPS2. Biallelic GJB2 (connexin-26) mutations cause a distinct autosomal-recessive syndrome of ichthyosis follicularis + severe sensorineural hearing loss + punctate palmoplantar keratoderma (Youssefian 2019, 2022), and SREBF1 variants cause autosomal-dominant IFAP that overlaps hereditary mucoepithelial dysplasia (HMD) — both broaden the differential diagnosis. MBTPS2 is also allelic to X-linked Olmsted syndrome (contrasting with autosomal-dominant TRPV3 Olmsted; Duchatelet 2014). Omics profiling of S2P-mutant patient fibroblasts (studied in the allelic OI type XIX context) revealed perturbations in fatty-acid metabolism and collagen production as a molecular signature of MBTPS2 deficiency (Lim 2021, 2023).

"association of a new syndrome of an autosomal recessive disorder of ichthyosis follicularis, bilateral severe sensorineural hearing loss and punctate palmoplantar keratoderma with mutations in GJB2" — PMID: 30431684

Mechanistic Model / Interpretation

The unifying model of IFAP Syndrome 1 is a dose-dependent partial failure of regulated intramembrane proteolysis. Site-2 protease sits at a metabolic and stress-signaling nexus: it is required both to activate SREBP (governing membrane lipid supply) and to activate ATF6 (governing the ER's adaptive response to folding stress). Tissues with the highest demand for barrier lipids and epithelial renewal — the epidermis, hair follicle, and corneal/limbal epithelium — are the most vulnerable when S2P output falls, explaining the specificity of the IFAP triad despite the gene's ubiquitous expression.

Low sterol / lipid demand
│
▼
 SCAP escorts SREBP  ER ──▶ Golgi
│
▼
 S1P (MBTPS1) cleaves SREBP (cut 1, luminal)
│
▼
 S2P (MBTPS2) cleaves SREBP (cut 2, INTRAMEMBRANE)  ◀── DEFECTIVE IN IFAP
│
▼
 Active SREBP transcription factor → nucleus
│
▼
 ↑ Cholesterol + fatty-acid biosynthesis genes
│
   (parallel arm)
 ER stress → ATF6 → same S1P/S2P cleavage → UPR target genes  ◀── ALSO DEFECTIVE

Causal chain. Hypomorphic MBTPS2 → reduced intramembrane cleavage of SREBP and ATF6 → (a) deficient cholesterol/fatty-acid synthesis → defective epidermal barrier lipids and abnormal keratinization (ichthyosis follicularis, keratoderma), abnormal hair-follicle differentiation (atrichia), and corneal/limbal epithelial failure (keratopathy → photophobia); and (b) failure of the ATF6/UPR ER-stress response → impaired handling of ER protein-folding load, contributing to cellular dysfunction and (with NF-κB dysregulation) recurrent infection. Upstream = loss of S2P proteolytic activity; downstream = tissue-specific differentiation and stress-response failures.

Two features of this model are clinically important. First, residual activity predicts severity — a graded relationship rather than an all-or-none one (PMID: 19361614), which is why the same gene yields disorders ranging from isolated KFSD/IFAP to lethal BRESHECK. Second, the S2P–NF-κB link (PMID: 37267109) provides a mechanistic explanation for the recurrent infections that are otherwise puzzling in a "keratinization" disorder, integrating the barrier defect with an intrinsic innate-immune signaling defect.

         MBTPS2 (S2P) activity  ───────────────────────────►  high
   BRESHECK ◄──── lethal multisystem      IFAP full triad     mild/atypical
   (little residual activity)         (intermediate)        (more residual)

Comprehensive Section-by-Section Report

1. Disease Information

Overview. IFAP Syndrome 1 is a rare congenital ectodermal disorder defined by the triad of ichthyosis follicularis, atrichia (alopecia), and photophobia. It is a multisystem genodermatosis: beyond the diagnostic triad, patients commonly show palmoplantar keratoderma, nail dystrophy, recurrent skin/respiratory infections, growth impairment, and (in more severe cases) neurodevelopmental and multi-organ anomalies.

Synonyms / alternative names. IFAP syndrome; Ichthyosis Follicularis–Alopecia–Photophobia syndrome; Ichthyosis Follicularis with Atrichia and Photophobia. The severe multisystem extension is BRESHECK syndrome. Note: IFAP2 (OMIM #619016) is a distinct autosomal-dominant form caused by SREBF1 and overlapping hereditary mucoepithelial dysplasia (HMD) — this report focuses on the MBTPS2 (X-linked) form.

Source of information. The information base is disease-level aggregated (case reports, small case series, and functional/molecular studies) rather than large EHR/individual-patient cohorts — reflecting the disease's extreme rarity (~40 reported male cases as of 2018; PMID: 28654459).

2. Etiology

Causal factor. The primary cause is genetic: hypomorphic (partial loss-of-function) missense and splice-site variants in MBTPS2 (PMID: 19361614). No environmental or infectious cause initiates the disease.

Genetic risk factors. The causal variants are germline MBTPS2 variants; because the gene is X-linked, male sex (hemizygosity) is the principal risk determinant. Residual protease activity (an intrinsic property of the specific variant) determines severity. No independent susceptibility loci or common-variant risk factors are described. Complete loss of function is presumed embryonic-lethal; only partial-function alleles are viable.

Environmental risk / protective factors. None established. There is no known diet, exposure, or lifestyle factor that causes, worsens, or protects against IFAP. Heat, low humidity, and bright light exacerbate the symptoms (xerosis, photophobia) but are not disease-modifying. In carrier females, favorably skewed X-inactivation can reduce or abolish manifestations (PMID: 16720460).

Modifier genes / stochastic factors. Variable expressivity of identical variants (e.g., c.671-9T>G with vs without keratoderma; PMID: 24313295) implies genetic modifiers and/or stochastic X-inactivation influence severity, but no specific modifier gene is identified.

Gene–environment interactions. None formally demonstrated. Given the mechanistic link between S2P and NF-κB-mediated innate immunity (PMID: 37267109), infectious exposures may plausibly interact with the immune-signaling defect to drive recurrent infections, but this is inferential.

3. Phenotypes

Onset is congenital/neonatal for cutaneous and hair features; the triad is highly penetrant in affected males with variable expressivity. Course is chronic and lifelong; the keratopathy is progressive.

Quality-of-life impact. Substantial — chronic scaly/pruritic skin, disfiguring universal alopecia (psychosocial burden), progressive visual impairment/blindness impairing education and mobility, recurrent infections, and (in severe cases) intellectual disability and organ malformations. No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare disease.

4. Genetic / Molecular Information

• Causal gene: MBTPS2 (HGNC:7375; NCBI Gene 51360; UniProt Q9UHC9), Xp22.12; a ~520-aa polytopic membrane zinc metalloprotease (site-2 protease, S2P; M50 peptidase family, HExxH…LDG zinc-binding motif).
• Variant classification (ACMG/AMP): Reported variants are Pathogenic/Likely Pathogenic when supported by functional assays; CHO-M19 complementation provides PS3-level evidence. Splice/intronic variants often require mini-gene/cDNA validation to upgrade from VUS.
• Variant types: Predominantly missense (exchanging highly conserved residues; PMID: 19361614); also splice-site/intronic — c.671-9T>G (PMID: 24313295), c.970+5G>A → exon-7 skipping (PMID: 36539961), and c.766G>A/p.Val256Leu in BRESHECK (PMID: 34655156).
• Allele frequency: Pathogenic variants are private/ultra-rare; essentially absent from gnomAD (consistent with X-linked reproductive selection).
• Origin: Germline, X-linked; transmitted by carrier mothers or de novo. No somatic/cancer role.
• Functional consequence: Hypomorphic (partial loss of function) — residual activity inversely correlated with severity; complete LOF presumed lethal.
• Modifier genes: None identified; variable expressivity implicates modifiers + X-inactivation.
• Epigenetics: No disease-specific methylation/histone data; X-chromosome inactivation is the key epigenetic determinant of the mosaic carrier-female phenotype (PMID: 16720460).
• Chromosomal abnormalities: None (point/splice mutations only; no recurrent CNV/translocation).
• Allelic disorders: IFAP ± BRESHECK, KFSD (OMIM #308800), X-linked Olmsted syndrome, and OI type XIX (PMID: 33743732).

5. Environmental Information

No environmental, lifestyle, or infectious etiological factors are known. IFAP is entirely genetically determined. Low humidity, heat, and mechanical trauma exacerbate xerosis and follicular hyperkeratosis; bright light exacerbates photophobia. Recurrent infections are a consequence of the disorder (barrier defect + impaired S2P/NF-κB innate immunity), not an environmental cause. One report links IFAP to Hodgkin lymphoma (PMID: 28654459), raising but not establishing a possible malignancy predisposition.

6. Mechanism / Pathophysiology

Molecular pathways. SCAP–SREBP lipogenesis (S1P/MBTPS1 then S2P/MBTPS2 cleave SREBP in the Golgi; PMID: 20935466); ATF6 branch of the UPR (same S1P/S2P machinery); NF-κB innate-immune signaling (PMID: 37267109). KEGG: SREBP/lipid biosynthesis; Protein processing in ER.

Cellular processes. Keratinocyte terminal differentiation and lamellar-body lipid secretion; corneal limbal stem cell maintenance; hair-follicle morphogenesis; ER-stress adaptation.

Protein dysfunction. Point/splice mutations reduce catalytic/structural function of the membrane metalloprotease (partial LOF; not aggregation). In vitro, p.Val256Leu produced "impaired cell growth in cholesterol-depleted media, attenuated activation of the sterol regulatory element-binding protein pathway, and failure to activate the endoplasmic reticulum stress response pathway" (PMID: 34655156).

Metabolic changes. Deficient cholesterol/fatty-acid (barrier lipid) synthesis. CHEBI: cholesterol (CHEBI:16113), sterol (CHEBI:15889), fatty acid (CHEBI:35366), zinc(2+) (CHEBI:29105).

Immune involvement. Recurrent infections; mechanistic link via S2P→NF-κB (PMID: 37267109) and barrier failure. Not autoimmune.

Tissue-damage mechanisms. Corneal neovascularization and conjunctivalization from limbal stem cell dysfunction; epidermal barrier disruption.

GO / CL suggestions. SREBP signaling GO:0032933; response to ER stress GO:0034976; metalloendopeptidase activity GO:0004222; cholesterol biosynthetic process GO:0006695; keratinocyte differentiation GO:0030216. Cells: keratinocyte (CL:0000312), corneal epithelial cell (CL:0000575), fibroblast (CL:0000057).

Molecular profiling (omics). No transcriptomic/proteomic/metabolomic dataset specific to IFAP itself. The nearest data are omics of S2P-mutant patient fibroblasts (allelic OI type XIX), revealing perturbations in fatty-acid metabolism and collagen production (PMID: 34093655; PMID: 37305034) — consistent with the SREBP-lipogenesis mechanism. IHC in the SREBF1 form showed reduced nuclear SREBP1 translocation with IL-17A/S100A8 upregulation (PMID: 39912473).

7. Anatomical Structures Affected

Lateralization. Cutaneous and ocular disease is bilateral/symmetric in affected males; female carriers show asymmetric, Blaschko-linear (mosaic) distribution due to lyonization.

8. Temporal Development

• Onset: Congenital/neonatal for skin/hair; photophobia/keratopathy emerge in infancy and progress. Onset pattern chronic/insidious.
• Progression: Cutaneous features relatively stable-to-slowly progressive; ocular keratopathy is inexorably progressive — "Males with IFAP have an inexorable progression of corneal vascularization and loss of vision" (PMID: 15370546). Chronic/lifelong; no spontaneous remission. Rare progressive musculoskeletal contractures (PMID: 41458897).
• Critical periods: Infancy/early childhood is the key window for ocular-surface protection to preserve vision; the neonatal period is critical in severe/BRESHECK cases (thermoregulation, infection, organ malformations).

9. Inheritance and Population

• Inheritance: X-linked recessive (MBTPS2, Xp22.12); affected males inherit from carrier mothers or de novo; no male-to-male transmission; all daughters of an affected male are obligate carriers.
• Penetrance / expressivity: High penetrance in hemizygous males; markedly variable expressivity, even for identical alleles (PMID: 24313295).
• Epidemiology: Ultra-rare (Orphanet ORPHA:2273); ~40 reported male cases by 2018 (PMID: 28654459); no reliable prevalence/incidence.
• Anticipation: Not applicable (no repeat expansion). Founder effects/consanguinity: none established (recurrent variants reflect mutational hotspots, not founders). Carrier frequency: not estimable (private variants, absent from gnomAD). Germline mosaicism: plausible but not well documented; de novo variants reported.
• Demographics: Reported worldwide (Australia, China, India, Brazil, Saudi Arabia, Korea, etc.) with no ethnic clustering; strongly male-predominant sex ratio; rare, generally milder female cases (including an atypical female with severe contractures and no photophobia, PMID: 41458897). A large Australian kindred clearly demonstrated X-linked transmission (PMID: 19689518).

10. Diagnostics

• Clinical diagnosis: Recognition of the triad (follicular ichthyosis + congenital atrichia + photophobia).
• Skin biopsy/histopathology: Orthokeratotic hyperkeratosis, acanthosis, and follicular plugging (PMID: 41458897); reduced/absent hair follicles.
• Ophthalmology: Slit-lamp (corneal vascularization, epithelial defects, pannus); anterior-segment OCT (abnormal hyperreflective epithelium indicating limbal stem cell dysfunction; PMID: 32482964); carrier mothers may show retinal vascular tortuosity.
• Genetic testing (confirmatory): MBTPS2 single-gene sequencing or WES/WGS; ichthyosis/ectodermal-dysplasia panels. Splice/intronic VUS require cDNA/mini-gene assays (PMID: 36539961); CHO-M19 complementation assesses residual function (PMID: 19361614). CMA/karyotype/FISH generally uninformative.
• Clinical criteria: No formal consensus criteria; diagnosis is triad + molecular confirmation.
• Differential diagnosis (IF is genetically heterogeneous): SREBF1-IFAP / HMD — autosomal dominant (PMID: 33742461; PMID: 41492963); GJB2 — autosomal recessive IF + severe SNHL + punctate PPK (PMID: 30431684; PMID: 35396755); KFSD; Olmsted syndrome (X-linked MBTPS2 vs AD TRPV3, PMID: 24452206); other congenital ichthyoses/ectodermal dysplasias.
• Screening: No newborn/population screening. Cascade carrier testing of at-risk female relatives; prenatal/PGT when familial variant is known.

11. Outcome / Prognosis

• Survival/mortality: Isolated (non-BRESHECK) IFAP is compatible with near-normal life expectancy; BRESHECK carries high infant/childhood morbidity and mortality from brain/kidney anomalies, infections, and marrow involvement (PMID: 34655156). No formal survival statistics.
• Morbidity/disability: Dominated by progressive visual impairment/blindness, chronic skin disease, recurrent infections, and, in severe cases, intellectual disability and organ dysfunction; rare disabling contractures.
• Complications: Corneal scarring/blindness, secondary infections, growth failure; possible malignancy (single Hodgkin lymphoma case, PMID: 28654459).
• Recovery potential: No cure; features largely irreversible, though skin and corneal erosions can partially improve with therapy.
• Prognostic factors: Residual MBTPS2 activity / genotype severity is the principal determinant (PMID: 19361614); BRESHECK features predict poor outcome. No validated prognostic biomarkers.

12. Treatment

No curative/disease-modifying therapy; symptomatic, multidisciplinary (dermatology, ophthalmology, genetics ±). Suggested NCIT terms in parentheses.

Advanced/experimental therapies. No gene, cell, RNA, or targeted therapies are approved or in trials; no NCT-registered IFAP-specific interventional trials identified. Pharmacogenomics not applicable. Genotype (residual activity) may guide severity expectation/counseling, but no genotype-directed drug exists. Retinoid toxicity (mucocutaneous, hepatic, lipid, skeletal) and teratogenicity require monitoring.

13. Prevention

• Primary prevention: Not possible (monogenic germline). Genetic counseling and reproductive options (carrier testing, prenatal diagnosis, PGT-M) for at-risk families are the mainstay.
• Secondary prevention: Early ophthalmologic surveillance and ocular-surface protection in infancy to slow corneal vascularization and preserve vision; early skin care.
• Tertiary prevention: Infection prophylaxis/prompt treatment, vision rehabilitation, nutritional/growth support, management of BRESHECK complications.
• Screening: Cascade genetic testing of relatives; no population/newborn screening. Routine vaccination advisable given infection risk. Behavioral/public-health/environmental interventions are not applicable to causation.

14. Other Species / Natural Disease

• Taxonomy / orthologs: MBTPS2 is deeply conserved. Human MBTPS2 (Taxon 9606); mouse Mbtps2 (Taxon 10090; NCBI Gene 270669); Drosophila S2P (Taxon 7227); hamster ortholog underlies the classic M19 mutant cell line (Taxon 10029).
• Natural disease in other species: No naturally occurring IFAP-equivalent disease is catalogued in OMIA for companion animals or livestock; veterinary relevance is minimal.
• Comparative biology / conservation: The S2P–SREBP lipid-regulatory axis is conserved from insects to mammals; Drosophila ds2p nulls show lipid-auxotrophy phenotypes (PMID: 20935466), underscoring conserved essentiality.
• Transmission: Not applicable (non-infectious, non-zoonotic).

15. Model Organisms

Gap: No dedicated Mbtps2 mouse or zebrafish IFAP disease model was identified; whole-animal null models are expected to be lethal. Mechanistic inference relies on cellular complementation and orthologous invertebrate genetics. Resources: MGI (Mbtps2), FlyBase (S2P), Cellosaurus (M19/CHO), plus patient-derived cells.

Evidence Base

Supported and Refuted Hypotheses

Supported: 1. IFAP1 is caused by partial LOF of MBTPS2, with residual activity inversely proportional to severity (PMID: 19361614; PMID: 34655156). 2. Photophobia results from a progressive keratopathy due to limbal stem-cell dysfunction, not a primary retinal defect (PMID: 15370546; PMID: 32482964). 3. Acitretin partially improves skin/corneal features but not alopecia/photophobia (PMID: 16268889; PMID: 21670910).

Refuted / not supported: - IFAP is not caused by environmental or infectious agents; no environmental or protective genetic modifiers are proven. - No animal model fully recapitulates the triad; claims of a definitive mouse/zebrafish IFAP model are not supported by retrieved literature.

Limitations and Knowledge Gaps

1. Small evidence base. With ~40 reported cases, all clinical claims derive from case reports/series; no controlled trials, no formal prevalence/incidence, and no validated QoL metrics exist.
2. No animal disease model. No Mbtps2 mouse or zebrafish IFAP model was identified; mechanistic inference relies on CHO-M19 cells, patient fibroblasts, and Drosophila — none of which reproduce the skin/eye phenotype.
3. Genotype–phenotype resolution is incomplete. Although residual activity correlates with severity, identical variants can produce divergent phenotypes (PMID: 24313295), implying unidentified modifiers or stochastic X-inactivation effects.
4. Treatment evidence is anecdotal. Acitretin benefit rests on individual cases; optimal dosing, long-term outcomes, and ocular-therapy standardization are undefined.
5. Uncertain associations. The single Hodgkin-lymphoma report does not establish a malignancy risk; the S2P–NF-κB immune link is mechanistically plausible but not clinically proven in IFAP patients.
6. Citation caveat. One omics snippet (PMID: 34093655) was flagged as title-derived during validation; the omics conclusion should be treated as supported primarily by the paired PMID: 37305034.

Proposed Follow-up Experiments / Actions

1. Generate a conditional Mbtps2 hypomorphic mouse (epidermis- and cornea-specific) to establish the first mammalian IFAP disease model and test whether residual-activity gradients recapitulate the human severity continuum.
2. Single-cell / spatial transcriptomics of IFAP skin and limbus to define cell-type-specific SREBP/ATF6 target-gene failure and confirm limbal stem-cell depletion at molecular resolution.
3. Systematic variant-function mapping in the CHO-M19 assay for all reported MBTPS2 variants to build a quantitative activity-vs-severity calibration usable for prognostic counseling.
4. Prospective natural-history registry (multinational, given rarity) capturing standardized ophthalmic, dermatologic, and QoL endpoints.
5. Pilot limbal stem-cell / amniotic-membrane protocols with pre-specified visual-acuity endpoints to move ocular management beyond anecdote.
6. Lipidomic/metabolomic profiling of patient skin and serum to test whether topical lipid replacement (cholesterol/fatty-acid supplementation) can bypass the SREBP defect — a mechanistically rational, low-risk therapeutic hypothesis.
7. Evaluate innate-immune function (NF-κB responsiveness) in patient monocytes to determine whether recurrent infections warrant prophylactic strategies.

Report compiled from 9 confirmed findings and 28 reviewed publications. Evidence classes: human clinical (case reports/series), in vitro (CHO-M19 complementation, mini-gene/splicing assays, IHC), invertebrate model (Drosophila), and computational/omics. PMIDs cited inline.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0100213 (4 mentions) - the report calls it "MONDO"; MONDO calls it IFAP syndrome 1, with or without BRESHECK syndrome
• HP:0033052 (1 mention) - the report calls it "Angular cheilitis / periorificial keratotic plaques"; HP calls it Non-epileptic seizure

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• NCIT:C29496 (1 mention), reported as "Acitretin ~1 mg/kg" - NCIT does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0016021 (GO_0016021) (1 mention) - replaced by GO:0016020

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0008404 (1 mention) - the report calls it "Nail dystrophy / pachyonychia"; HP calls it Nail dystrophy
• HP:0000958 (1 mention) - the report calls it "Xerosis / dry skin"; HP calls it Dry skin
• HP:0002719 (1 mention) - the report calls it "Recurrent infections (skin/respiratory)"; HP calls it Recurrent infections
• HP:0001510 (1 mention) - the report calls it "Growth retardation / short stature"; HP calls it Growth delay, and lists "Growth retardation" among its other names
• HP:0001249 (1 mention) - the report calls it "Intellectual disability / developmental delay"; HP calls it Intellectual disability
• HP:0034392 (1 mention) - the report calls it "Joint contractures (rare)"; HP calls it Joint contracture

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.